GlassScriptPhysician profile
James Phillip Herd
NPI 1972520575
$8,798.69
in general payments reported to CMS, 2019-2025
15 companies · $3,273 in 2025
The $3,273 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $121 · 2021: $1,840 · 2022: $14.33 · 2023: $185 · 2024: $2,702 · 2025: $3,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,600 · Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,600.00 |
| Food and Beverage | $560.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $5,600.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $2,115.70 | 2019-2022 | |
| Exeltis, USA INC. | $235.80 | 2025 | Slynd, Twirla |
| Minerva Surgical, INC | $184.38 | 2019 | |
| Hologic Sales and Service, LLC | $166.34 | 2023 | Acessa Provu System |
| Medtronic, INC. | $130.31 | 2021 | |
| Therapeuticsmd, INC. | $119.95 | 2019 | |
| Avion Pharmaceuticals | $53.93 | 2019-2020 | |
| Astellas Pharma US INC | $40.82 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $35.70 | 2023-2025 | Myfembree |
| Ethicon US, LLC | $34.26 | 2020-2021 | |
| Davol INC. | $23.97 | 2024 | Arista Ah Flexitip |
| Coopersurgical, INC. | $23.32 | 2024 | Endosee |
| Biogen, INC. | $20.72 | 2025 | Zurzuvae |
| Ascend Therapeutics US, LLC | $13.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Herd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.